Abstracts Archive - Page 746 of 2425 - ACR Meeting Abstracts

Abstract Number: 1370 • ACR Convergence 2020
A Delayed Effect of Tumor Necrosis Factor Inhibitors on Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: Long-term Results from the German Spondyloarthritis Inception Cohort
Denis Poddubnyy¹, Valeria Rios Rodriguez², Murat Torgutalp², Ani Dilbaryan², Maryna Verba², Mikhail Protopopov², Fabian Proft², Judith Rademacher², Hildrun Haibel², Joachim Sieper² and Martin Rudwaleit³, ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany
Background/Purpose: There are inconclusive data on the effect of tumor necrosis factor inhibitors (TNFi) on radiographic spinal progression in axial spondyloarthritis (axSpA). Although inflammation and…
Abstract Number: 1371 • ACR Convergence 2020
Improvement in Patient-Reported Outcomes for Upadacitinib versus Placebo Among Patients with Psoriatic Arthritis and an Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs
Vibeke Strand¹, Filip Van den Bosch², Roberto Ranza³, Ying Ying Leung⁴, Edit Drescher⁵, Apinya Lertratanakul⁶, Ralph Lippe⁷, Christopher Saffore⁶, Patrick Zueger⁶ and Peter Nash⁸, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Ghent University Hospital, Ghent, Belgium, ³Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlândia, Brazil, ⁴Department of Rheumatology & Immunology, Singapore General Hospital, Singapore, Singapore, ⁵Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸School of Medicine Griffith University, Brisbane, Queensland, Australia
Background/Purpose: The efficacy and safety of upadacitinib (UPA), a selective Janus kinase inhibitor, in patients with PsA is under investigation in Phase 3 clinical trials.…
Abstract Number: 1372 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis and Axial Involvement
Atul Deodhar¹, Roberto Ranza², Fabiana Ganz³, Tianming Gao⁴, Jaclyn K Anderson⁴ and Andrew Östör⁵, ¹Oregon Health & Science University, Portland, OR, ²Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlândia, Brazil, ³AbbVie Inc., Baar, Switzerland, ⁴AbbVie Inc., North Chicago, IL, ⁵Cabrini Medical Center, Monash University, Malvern, Victoria, Australia
Background/Purpose: Upadacitinib (UPA) has demonstrated efficacy for the treatment of AS in patients (pts) who were NSAID inadequate responders (IR).1 Pts with psoriatic arthritis (PsA)…
Abstract Number: 1373 • ACR Convergence 2020
IL-23 Skin and Joint Profiling in Psoriatic Arthritis: Novel Perspectives in Understanding Clinical Responses to IL-23 Inhibitors
Alessandra Nerviani¹, Marie-Astrid Boutet¹, Wang Sin Gina Tan¹, Katriona Goldmann¹, Nirupam Purkayastha¹, Tamas Lajtos¹, Rebecca Hands¹, Myles Lewis¹, Stephen Kelly² and Costantino Pitzalis³, ¹Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ²Mile End Hospital, Barts Health NHS Trust, London, United Kingdom, ³Queen Mary University of London, London, United Kingdom
Background/Purpose: PsA is a chronic heterogeneous inflammatory condition affecting up to 30% of patients with skin and/or nail psoriasis and the IL-23/IL-17 axis is believed…
Abstract Number: 1374 • ACR Convergence 2020
Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial
Bruce Kirkham¹, Peter Nash², Sandra Navarra³, Erhard Quebe-Fehling⁴, Corine Gaillez⁴, Carlos Sastre⁴ and Philip Mease⁵, ¹Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³University of Santo Tomas, Manila, Philippines, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Dactylitis is a key and frequent clinical manifestation of psoriatic arthritis (PsA)1 associated with significant disease burden and impaired function.2–3 Randomized controlled trials designed…
Abstract Number: 1375 • ACR Convergence 2020
Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and Biologics in the Real Life?
Charlotte Baert¹, Charlene Mouafo Toukam², Tatiana Sokolova³, Maria S. Stoenoiu⁴, Patrick Durez⁵, Laurent Meric De Bellefon² and Adrien Nzeusseu Toukap⁶, ¹Rheumatology department, St-Luc university hospitals, Brussels, Belgium, ²Rheumatology department; St-Luc University Hospitals, Brussels, Belgium, ³Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁴1Department of Rheumatology, Cliniques Universitaires Saint-Luc, 2Institut de recherche expérimentale et cliniques (IREC), Brussels, Belgium, ⁵Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ⁶1Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium
Background/Purpose: Randomized-controlled trials (RCTs) done in axial spondyloarthritis (AxSpA) patients have shown that remission in Ankylosing Spondylitis and nonradiographic AxSpA patients treated without biologics (BIOL)…
Abstract Number: 1376 • ACR Convergence 2020
Impact of Body Composition Measures on the Response to Biological Disease-modifying Anti-rheumatic Drugs in Patients with Ankylosing Spondylitis
Valeria Rios Rodriguez¹, Mikhail Protopopov¹, Fabian Proft¹, Judith Rademacher¹, Burkhard Muche¹, Anne-Katrin Weber¹, Susanne Lüders¹, Hildrun Haibel¹, Maryna Verba¹, Joachim Sieper¹ and Denis Poddubnyy², ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Data on the impact of body weight and body mass index (BMI) on the response to biological disease-modifying anti-rheumatic drugs (bDMARDs) in axial spondyloarthritis…
Abstract Number: 1377 • ACR Convergence 2020
Raynaud’s Phenomenon and Systemic Sclerosis in Post-9/11 Deployed Veterans Receiving Care Veterans Health Administration Care
Tracy Frech¹, Maureen Murtaugh¹, Megan Amuan² and Mary Jo Pugh¹, ¹University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ²Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: The purpose of this project was to describe Raynaud's phenomenon (RP), very early diagnosis of systemic sclerosis (VEDOSS), and systemic sclerosis (SSc) in Veterans…
Abstract Number: 1378 • ACR Convergence 2020
Understanding Diagnostic Pathways in Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Shervin Assassi¹, Nan Shao², Ziwei Yin², Elizabeth Volkmann³, Donald Zoz² and Thomas Leonard², ¹University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ²Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, ³University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of SSc. SSc-ILD is usually detected in a patient known to have SSc, but ILD may…
Abstract Number: 1379 • ACR Convergence 2020
Clinical Outcomes Among Participants with Diffuse Systemic Sclerosis Contracting COVID-19 During Clinical Studies of Lenabasum: A Case Series
Robyn Domsic¹, Lorinda Chung², Jerry Molitor³, Robert Spiera⁴, Bradley Bloom⁵, Barbara White⁶ and Quinn Dinh⁶, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ³University of Minnesota, Minneapolis, MN, ⁴Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, ⁵Corbus Pharmaceuticals Inc, Norwood, MA, ⁶Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: Patients with systemic sclerosis (SSc) may be at increased risk for severe outcomes with COVID-19, given the high rate of immunosuppressive medication use, underlying…
Abstract Number: 1380 • ACR Convergence 2020
Digital Occlusive Arterial Disease on Laser Doppler Flowmetry Increases the Risk of Digital Ischemic Complications in Systemic Sclerosis: Results from a Single Center Referral Cohort (2001-2018)
Yasser Radwan¹, Tina Gunderson², Cynthia Crowson², David Liedl², Kenneth Warrington³, Paul Wennberg² and Ashima Makol², ¹Mayo Clinic, Rochester, Minnesota, USA, Lansing, MI, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Vascular dysfunction is a key feature of systemic sclerosis (SSc), manifesting clinically as Raynaud’s phenomenon (RP) with or without digital ischemia. Laser doppler flowmetry…
Abstract Number: 1381 • ACR Convergence 2020
Real-World Mono-, Double and Triple Combination Treatment Patterns with Macitentan in Patients with Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (PAH-CTD): Evidence from the Combined OPUS/OrPHeUS Dataset
Matthew Lammi¹, Kelly Chin², Nick H. Kim³, Vallerie McLaughlin⁴, Roham Zamanian⁵, Megan Flynn⁶, Sandrine Leroy⁷, Rose Ong⁷, Graham Wetherill⁷ and Richard Channick⁸, ¹Lousiana State University Health Sciences Center, New Orleans, LA, ²UT Southwestern Medical Center, Dallas, TX, ³University of California San Diego, La Jolla, CA, ⁴University of Michigan, Ann Arbor, MI, ⁵Stanford University School of Medicine, Stanford, CA, ⁶Actelion Pharmaceuticals US, Inc., South San Francisco, CA, ⁷Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, ⁸University of California Los Angeles, Los Angeles
Background/Purpose: Patients with PAH-CTD have a worse prognosis than patients with most other PAH etiologies. The OPsumit® USers (OPUS) Registry and OPsumit® Historical USers (OrPHeUS)…
Abstract Number: 1382 • ACR Convergence 2020
Changes in Imaging Markers in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib: Sub-Study of the SENSCIS Trial
Stephen Humphries¹, Eric Hachulla², Mark Hamblin³, Takashi Ogura⁴, Dag Wormanns⁵, Carina Ittrich⁶, Frank Risse⁶, Margarida Alves⁷, Martina Gahlemann⁸ and David Lynch⁹, ¹National Jewish Health, Denver, Colorado, USA, Denver, CO, ²Department of Internal Medicine and Clinical Immunology, Université de Lille, Lille, France, Lille, France, ³University of Kansas Hospital, Kansas City, Kansas, USA, Kansas City, KS, ⁴Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Centre, Yokohama, Japan, Yokohama, Japan, ⁵Evangelische Lungenklinik, Berlin, Germany, Berlin, Germany, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, Biberach an der Riss, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁹National Jewish Health, Denver, Colorado, USA, Denver
Background/Purpose: In the SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52 weeks by…
Abstract Number: 1383 • ACR Convergence 2020
Tocilizumab Shows Potential in Preserving Lung Function in Systemic Sclerosis with Positive anti-topoisomerase-1 (Scl-70): A Single Centre Cohort Study
Yasir Suleman¹, Kristina Clark², Svetlana Nihtyanova³, Voon Ong⁴ and Christopher Denton², ¹Royal Free Hospital London NHS Trust, London, United Kingdom, ²University College London, London, United Kingdom, ³Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, ⁴UCL, London, United Kingdom
Background/Purpose: Recent Phase II (faSScinate) and Phase III (focuSSced) clinical trials of tocilizumab versus placebo in early dcSSc highlighted the potential impact of tocilizumab on…
Abstract Number: 1384 • ACR Convergence 2020
Usage, Needs and Preferences Regarding Physical Therapy in Patients with Systemic Sclerosis
Sophie Liem¹, Nina van Leeuwen², Thea Vliet Vlieland³, Lian de Pundert⁴, Rita Schriemer⁵, Julia Spierings⁶, Madelon Vonk⁷ and Jeska de Vries-Bouwstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³Leiden University Medical Center, 2300 RC Leiden, Netherlands, ⁴HAGA Hospital, The Hague, Netherlands, ⁵NVLE, Utrecht, ⁶University Medical Center Utrecht, Maastricht, Netherlands, ⁷Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Netherlands
Background/Purpose: The importance of non-pharmacologic interventions in systemic sclerosis (SSc) is increasingly recognized. Physical therapy is among the most frequently used interventions, but knowledge on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].